AMAG Pharmaceuticals Target of Unusually High Options Trading (AMAG)
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was the recipient of some unusual options trading on Thursday. Stock traders acquired 1,049 put options on the stock. This is an increase of approximately 854% compared to the typical daily volume of 110 put options.
AMAG Pharmaceuticals (NASDAQ:AMAG) opened at $19.60 on Friday. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $24.85. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.60 and a current ratio of 1.74. The stock has a market capitalization of $669.85, a price-to-earnings ratio of 93.57 and a beta of 0.28.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.68. AMAG Pharmaceuticals had a positive return on equity of 0.96% and a negative net margin of 32.66%. The business had revenue of $158.30 million for the quarter, compared to the consensus estimate of $158.84 million. During the same quarter in the prior year, the company earned ($0.31) EPS. The business’s revenue was up 4.4% compared to the same quarter last year. research analysts forecast that AMAG Pharmaceuticals will post -3.25 earnings per share for the current fiscal year.
Several equities analysts have commented on AMAG shares. B. Riley upped their price objective on AMAG Pharmaceuticals from $16.00 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, March 14th. BidaskClub downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 10th. Jefferies Group downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price objective for the company from $21.00 to $20.00 in a research report on Monday, March 5th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $20.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, March 1st. Finally, Morgan Stanley upped their price objective on AMAG Pharmaceuticals from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. Twelve investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. AMAG Pharmaceuticals has an average rating of “Hold” and a consensus target price of $23.91.
COPYRIGHT VIOLATION NOTICE: “AMAG Pharmaceuticals Target of Unusually High Options Trading (AMAG)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/amag-pharmaceuticals-target-of-unusually-high-options-trading-amag/1959474.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.